Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 6
Submit an article Journal homepage
264
Views
4
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort

Angela GrelaudInserm CIC1401, Bordeaux, France; ;Univ. Bordeaux, Bordeaux, France;
,
Annie Fourrier-RéglatInserm CIC1401, Bordeaux, France; ;Univ. Bordeaux, Bordeaux, France; ;Inserm U657, Bordeaux, France; ;CHU Bordeaux, Bordeaux, France;
,
Olivier FitoussiPolyclinique Bordeaux Nord, Bordeaux, France;
,
Thierry FaconCHU Lille, Lille, France;
,
Jérémy JovéInserm CIC1401, Bordeaux, France; ;Univ. Bordeaux, Bordeaux, France;
,
Jacques BénichouInserm U657, Bordeaux, France; ;CHU Rouen, Rouen, France
,
Philip RobinsonInserm CIC1401, Bordeaux, France; ;Univ. Bordeaux, Bordeaux, France;
,
Gérald MaritCHU Bordeaux, Bordeaux, France;
,
Magali RouyerInserm CIC1401, Bordeaux, France; ;Univ. Bordeaux, Bordeaux, France;
,
Nicholas MooreInserm CIC1401, Bordeaux, France; ;Univ. Bordeaux, Bordeaux, France; ;Inserm U657, Bordeaux, France; ;CHU Bordeaux, Bordeaux, France;
,
Pernelle NoizeInserm CIC1401, Bordeaux, France; ;Univ. Bordeaux, Bordeaux, France; ;Inserm U657, Bordeaux, France; ;CHU Bordeaux, Bordeaux, France; Correspondence[email protected]
& the VESUVE Study Group show all
Pages 1349-1354 | Received 19 Jun 2015, Accepted 14 Sep 2015, Published online: 16 Nov 2015

References

  • Palumbo A, Mina R. Management of older adults with multiple myeloma. Blood Rev 2013; 27: 133–142.
  • Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010; 28: 3160–3166.
  • Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118: 4519–4529.
  • Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27: 3664–3670.
  • Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831.
  • Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209–1218.
  • Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010; 116: 1405–1412.
  • Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137: 429–435.
  • San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917.
  • Mateos MV, Oriol A, Martinez-Lopez J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 2014; 124: 1887–1893.
  • Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23: 1716–1730.
  • Fourrier-Reglat A, Noize P, Facon T, et al. Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study. Leuk Lymphoma 2014; 55: 848–854.
  • Velcade® SmPC. London, UK: European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000539/WC500048471.pdf. Accessed September 19, 2014.
  • Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
  • Palumbo A, Mateos MV, Bringhen S, et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 2011; 25: 181–191.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.